One person experienced hypothermia symptoms and another reported post-vaccination stress.
The study said limitations of the analysis included reliance on data provided by healthcare providers and those who got vaccinated, which might lead to under-reporting of cases.
Although it is reported that the AstraZeneca vaccine presents a small risk of developing potentially fatal blood clots, the chances of developing such a condition are around 1 in 600,000, which is about 10% of the risk presented by the initial dose for people between the ages of 18 and 49.